Key result
Oral aloe vera significantly reduced fasting blood glucose by 46.6 mg/dL (p<0.0001) and HbA1c by 1.05% (p=0.004) in prediabetic and diabetic populations.
Why the study?
Does oral aloe vera reduce fasting blood glucose and hemoglobin A1c in prediabetic and diabetic populations?
Population
Prediabetic and diabetic populations (9 studies, n=283 for FBG; 5 studies, n=89 for HbA1c)
Design
Meta-analysis
Authors
Loading...
Supports adjunctive oral aloe vera for glycemic control; extends prior trial evidence in prediabetes and diabetes.
Meta-Analysis (n=283)
Does oral aloe vera reduce fasting blood glucose and hemoglobin A1c in prediabetic and diabetic populations?
Mean Difference: -46.6
p-value: p=<0.0001
Oral aloe vera consumption significantly reduces fasting blood glucose and HbA1c in prediabetic and diabetic patients, with potentially greater benefits in those with baseline FBG ≥200 mg/dL.
Dick et al. (2016) conducted a meta-analysis in Prediabetes and diabetes mellitus (n=283). Oral aloe vera vs. Baseline was evaluated on Reduction of fasting blood glucose (FBG) (MD -46.6 mg/dL, p=<0.0001). Oral aloe vera significantly reduced fasting blood glucose by 46.6 mg/dL (p<0.0001) and HbA1c by 1.05% (p=0.004) in prediabetic and diabetic populations.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: